Difficulties in assessing appropriate ondansetron use.
Schwarz
L R
LR
D000970:Antineoplastic Agents / Q000009:adverse effects; D006801:Humans; D017294:Ondansetron / Q000008:administration & dosage* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000970:Antineoplastic Agents; D017294:Ondansetron